Fermenta Biotech is currently trading at Rs. 637.05, up by 34.80 points or 5.78% from its previous closing of Rs. 602.25 on the BSE.
The scrip opened at Rs. 615.00 and has touched a high and low of Rs. 648.00 and Rs. 610.00 respectively. So far 6772 shares were traded on the counter.
The BSE group ‘X’ stock of face value Rs. 5 has touched a 52 week high of Rs. 1125.00 on 10-Jan-2019 and a 52 week low of Rs. 583.00 on 14-Nov-2019.
Last one week high and low of the scrip stood at Rs. 698.00 and Rs. 583.00 respectively. The current market cap of the company is Rs. 623.99 crore.
The promoters holding in the company stood at 63.15%, while Institutions and Non-Institutions held 0.55% and 36.30% respectively.
Fermenta Biotech has opened a wholly owned subsidiary in Germany, to be closer to its customers. This subsidiary would also manufacture value-added products like D3 500 Feed grade, D3 100 Food grade etc. in Europe through third parties. These value-added products would typically be new variants wherein the company would utilise third party resources in terms of plant, equipment etc. This will strengthen its position in terms of quality, reach and tap into new customers without any additional CAPEX.
Fermenta Biotech is manufacturer and supplier of Vitamin D3 (Cholecalciferol), Leading supplier of Penicillin G Amidase, CAL B Lipase, Polymer Supports and enzyme technologies for beta lactams and Bio-Enzymes for Environmental Solutions waste water management and Lake & pond bioremediation.